Keywords: amgen, sees, slow, revenue, growth, 2nd-qtr, fda
Amgen sees slow revenue growth in 2nd-qtr 2007 as FDA warnings harm ESA drug sales
Article | 06 August 2007
World biotechnology giant Amgen's second-quarter 2007 net income totalled $1.02 billion, or $0.90 per share, versus $14.0 million, or $0.01 per share, in the like, ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Is failure to adopt business process management putting the pharma industry at risk?
- Ignyta acquires Actagene Oncology and entry into cancer personalized medicine
- New Zealand declines Alexion's funding application for Solaris
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- Elan makes "transformational" acquisitions and a divestment
